To provide further experimental corroboration of their overlapping role in the context of bladder cancer, we used the TCGA bladder cancer cohort to examine the effects of mutations in KDM6A and KMT2D on a number of putative downstream targets of the complex. This evidence concerns the gene KMT2D and urinary bladder cancer.